|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In this paper, we focus our interest on the dynamics alterations of the tumor-stroma interface at the ultrastructural level and to detect BRCA1 and BRCA2 mutations using next generation sequencing (NGS) of breast tumor tissue.
|
28730229 |
2017 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The occurrence of inactivating somatic mutations in sporadic breast tumors suggested the role of the BRCA1 gene in tumorigenesis in at least a minor group of patients with non-familial breast cancer.
|
15712267 |
2005 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We investigated the genetic mechanisms behind the second event in breast tumors from 17 BRCA1 and eight BRCA2 germ-line mutation carriers, as compared with 21 sporadic breast tumors.
|
10862052 |
2000 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The distribution of histopathological features of invasive breast tumors in BRCA1 or BRCA2 germline mutation carriers differs from that of individuals with no known mutation.
|
25857409 |
2014 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Little is known about miRNA deregulation in hereditary breast tumors as no miRNA expression profiling studies have been performed in normal breast tissue of BRCA1 and BRCA2 mutation carriers. miRNA profiles of 17 BRCA1- and 9 BRCA2-associated breast carcinomas were analyzed using microarrays.
|
26378051 |
2015 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Based on our initial experiments identifying a putative interaction between BRCA1 and the clock proteins Per1 and Per2, as well as the reported involvement of the circadian clock in the development of cancer, we have performed an expression analysis of the circadian clock genes Per1 and Per2 in both sporadic and familial primary breast tumors and normal breast tissues using real-time polymerase chain reaction.
|
17971899 |
2007 |
|
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Integrated analysis of the global gene methylation and expression profiles of a set of 33 familial breast tumours revealed that FOXA1 promoter methylation is inversely correlated with the transcriptional expression of FOXA1 and that BRCA1 mutation breast cancer is significantly associated with FOXA1 methylation and downregulation of FOXA1 expression, providing physiological evidence to our findings that FOXA1 expression is regulated by methylation and chromatin silencing and that BRCA1 maintains FOXA1 expression through suppressing FOXA1 gene methylation in breast cancer.
|
25531315 |
2015 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The BRCA1 positive breast tumours were significantly more often of ductal type, histological grade III and manifested a heavy lymphocyte infiltration.
|
9155518 |
1997 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Although ATM is involved in the DNA damage response, ATM-associated tumours are distinct from BRCA1-associated tumours in terms of morphological characteristics and genomic alterations, and they are also distinguishable from sporadic breast tumours, thus opening up the possibility to identify ATM variant carriers outside the ataxia-telangiectasia disorder and direct them towards effective cancer risk management and therapeutic strategies.
|
29665859 |
2018 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Only half of the basal-like breast tumors are actually deficient in BRCA1 expression.
|
21104783 |
2011 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Collectively, we propose that BRCA1/p220 loss of expression or function triggers BRCA1-IRIS overexpression through a post-transcriptional mechanism, which in turn promotes formation of aggressive and invasive breast tumors by inducing expression of TN/BL and survival proteins.
|
22431556 |
2012 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations.
|
18098285 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In the mouse, targeted deletion of Brca1 in luminal ER negative progenitors resulted in the formation of mammary tumours which phenocopied human BRCA1 breast tumour pathology, while the deletion of Brca1 in basal stem cells resulted in the formation of tumours which neither resembled human BRCA1 tumours or sporadic basal-like breast tumours.
|
21336547 |
2011 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
However, although BRCA1-related tumours are known to be predominantly basal-like, there are few published data on other classes of familial breast tumours.
|
19960244 |
2010 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Hormonal replacement experiments in ovariectomized mice showed that BRCA1-deficient mammary tumor formation is promoted by estrogen but not by progesterone.
|
29877575 |
2018 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Commercially available BRCA1 antibodies lack the specificity required to identify the BRCA1 protein and thus are not useful for establishing differences between familial and sporadic breast tumours, or between BRCA1 associated and non-BRCA1 associated breast tumours.
|
11376024 |
2001 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Germline mutations of the breast tumor suppressor gene BRCA1 predispose women to breast and ovarian cancers.
|
15187254 |
2004 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We used a breast cancer disease-specific microarray to identify transcripts that were differentially expressed between paraffin-embedded samples of 17 BRCA1-mutant and 14 sporadic breast tumors.
|
18000219 |
2007 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study, we aimed to investigate promoter methylation of three tumor-suppressor genes (BRCA-1, MGMT, and P16) and three histone marks (H3K9ac, H3K18ac, and H4K20me3) in patients with breast tumors.
|
30938887 |
2019 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We have previously shown that global gene expression analysis can identify unique and distinct expression profiles in breast tumors from BRCA1 and BRCA2 mutation carriers.
|
12610208 |
2003 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Although the BD-L signature is present in all subtypes of breast cancer, it is significantly higher in BRCA1 mutant primary tumors as compared with sporadic breast tumors.
|
24625110 |
2014 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability.
|
9592202 |
1998 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Such widespread genetic changes, together with recurrent loss of 5q and gain of 8q were reminiscent of those reported specifically for basal-like, estrogen receptor-negative, and BRCA1-associated breast tumors.
|
19047897 |
2009 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To determine if BRCA1 mutations explain a significant proportion of familial pancreatic cancer, we sequenced the BRCA1 gene in a large series of well-characterized patients with familial pancreatic cancer and we evaluated the pathology of breast neoplasms that developed in relatives of pancreatic cancer patients.
|
19029836 |
2009 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Loss of heterozygosity (LOH) of the wild-type BRCA1/2 allele is a reproducible event in breast tumors of BRCA1/2 mutation carriers, but it is unknown if this allelic loss occurs only in association with recognizable histopathologic abnormalities.
|
15104281 |
2004 |